Cargando…
Rapid and Sustained Symptom Relief in Patients With Ulcerative Colitis Treated With Filgotinib: Data From the Phase 2b/3 SELECTION Trial
Patients with ulcerative colitis (UC) regard rapid onset of action among the most important aspects of their treatment. We used the partial Mayo Clinic Score (pMCS) and component patient-reported subscores to assess the rapidity and sustainability of response to filgotinib, a once-daily, oral Janus...
Autores principales: | Danese, Silvio, Ferrante, Marc, Feagan, Brian G., Peyrin-Biroulet, Laurent, Hibi, Toshifumi, Sandborn, William J., Schreiber, Stefan, Ritter, Timothy, Loftus, Edward V., Rogler, Gerhard, Oortwijn, Alessandra, Yun, Chohee, Le Brun, Franck-Olivier, Dinoso, Jason, Hsieh, Jeremy, Vermeire, Séverine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810009/ https://www.ncbi.nlm.nih.gov/pubmed/36113491 http://dx.doi.org/10.14309/ajg.0000000000001979 |
Ejemplares similares
-
Corticosteroid-Sparing Effects of Filgotinib in Moderately to Severely Active Ulcerative Colitis: Data from the Phase 2b/3 SELECTION Study
por: Loftus, Edward V, et al.
Publicado: (2022) -
Filgotinib Improved Health-Related Quality of Life and Led to Comprehensive Disease Control in Individuals with Ulcerative Colitis: Data from the SELECTION Trial
por: Schreiber, Stefan, et al.
Publicado: (2023) -
Efficacy of Filgotinib in Patients with Ulcerative Colitis by Line of Therapy in the Phase 2b/3 SELECTION Trial
por: Dotan, Iris, et al.
Publicado: (2023) -
Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis
por: D’Amico, Ferdinando, et al.
Publicado: (2021) -
Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial
por: Hibi, Toshifumi, et al.
Publicado: (2023)